Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) has earned a consensus rating of “Moderate Buy” from the five ...

Analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Enanta Pharmaceuticals in a ...

A federal court in Massachusetts found in favor of Pfizer, whose oral Covid-19 treatment Paxlovid survived a patent challenge ...

Nearing five years since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, scientists continue to uncover the risk factors of blood clots and potential death for hospitalized and ...

Persistent high surf and flooding threats along California's coast have residents on high alert a day after a major storm was ...

Enanta Pharmaceuticals (ENTA) announced the United States District Court of Massachusetts has issued a ruling on a summary judgment ...

Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing RNA-based innovative therapies, today announced the successful dosing of the first patient in the Phase I ...

The Kurdish-led Syrian Democratic Forces says they have launched a counter-offensive against the Ankara-backed Syrian ...

Enanta Pharmaceuticals plans to appeal a court decision that Pfizer's Covid-19 antiviral drug, Paxlovid, doesn't infringe on its own patents. The U.S. District Court of Massachusetts ruled that Pfizer ...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule ...

Enanta Pharmaceuticals (NETA) stock fell as the company plans to appeal a court ruling favoring Pfizer in a patent dispute over COVID-19 pill Paxlovid. Read more here.

H.C. Wainwright analyst Ed Arce has maintained their bullish stance on ENTA stock, giving a Buy rating on December 13.Don't Miss Our Christmas ...